Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Upgraded by Wall Street Zen

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday.

ALNY has been the subject of several other reports. Citigroup assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They set a “buy” rating and a $380.00 price objective for the company. Royal Bank Of Canada cut their target price on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a research note on Friday, May 1st. Wells Fargo & Company lifted their target price on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a report on Friday, May 1st. HC Wainwright upped their price target on shares of Alnylam Pharmaceuticals from $470.00 to $485.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Truist Financial lowered their price target on Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a report on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $452.13.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $271.77 on Friday. The stock’s 50-day moving average is $292.22 and its 200-day moving average is $316.06. The company has a market cap of $36.28 billion, a price-to-earnings ratio of 74.25 and a beta of 0.27. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. Alnylam Pharmaceuticals has a 12 month low of $262.21 and a 12 month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the company posted ($0.44) EPS. The company’s revenue was up 96.4% compared to the same quarter last year. Equities analysts anticipate that Alnylam Pharmaceuticals will post 7.35 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares in the company, valued at approximately $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. MV Capital Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $25,000. HM Payson & Co. purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $27,000. Golden State Wealth Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 36 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $29,000. Finally, Manchester Capital Management LLC boosted its holdings in Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 72 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.